BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Biocitech SAS Welcomes Helios BioSciences to Its Technology Park


3/6/2012 10:19:03 AM

Biocitech, March 6, 2012 – Biocitech, the Paris life sciences technology park, announces the arrival of Helios BioSciences, a provider of bioinformatics services in support of the drug discovery process. Helios BioSciences, which moved into the technology park in December, is the 27th company to locate there. This is further confirmation of Biocitech’s attractiveness to firms that provide services along the whole of the human health value chain.

Helios BioSciences is specialized in research into new molecular targets and biomarkers. The company uses its proprietary, fully patented technological platform to build dynamic mathematic models of intracellular signalling cascades by combining available signalling data and experimental data. This makes it possible to identify potential targets whose activity can be modified in order to halt the disease. Another application of these models is the isolation of markers characterizing the evolution of the pathology or the response to treatments. Helios BioSciences focuses primarily on cancer, neurodegenerative and autoimmune diseases and helps companies rationalize their drug discovery processes in these areas in particular.

Founded in Paris in 2002, Helios BioSciences was originally housed in the Faculty of Medicine of Créteil, and also received support from the Paris Biotech Santé incubator at the Cochin Port-Royal Faculty of Medicine in Paris. It is funded by founders’ equity and business angels, as well as revenues from its fee-for-service activities, and has won prizes in the Ministry of Research/Tremplins Aventis competition for aid for the creation of innovative enterprises organized by the Aventis Foundation. The company currently has four employees.

“Helios BioSciences’ relocation to the Biocitech campus strengthens the range of services provided by the park’s scientific and technological service companies,” said Biocitech president, Jean-François Boussard. “Helios is positioned at the beginning of the drug R&D cycle. Our plug and market concept corresponds perfectly to the stage of development Helios is now at, and we think it will find some customers on its doorstep by talking to neighboring firms, as well as opportunities to develop joint product offers with other firms in the park.”

“Helios Biosciences’ novel positioning, downstream from the so-called “omic” platforms (transcriptomics, genomics, proteomics, metabolomics), gives us a real added value in the selection of therapeutic targets and biomarkers,” said the manager of Helios BioSciences, Jean-Baptiste Dumas. “Helios will be able to speed up its commercial development in a supportive environment. The premises, the services provided and the excellent standards with which Biocitech complies were behind our decision to relocate there.”

For further information, go to: http://www.helios-bioscience.com

About Biocitech

Biocitech is a technology park dedicated to life sciences and the environment. It offers resident companies on-site support from inception to maturity. It provides a range of services that are specifically designed for firms in the sectors of biotechnology, biopharmaceuticals, fine chemicals, medical and in vitro diagnostics and medical devices.

Biocitech is the only science and technology park in the Paris area that is ICPE certified and that offers a comprehensive and flexible range of services that include technical buildings, multi-technical services and support services. ICPE certification provides entrepreneurs with secure premises of a high technological standard that are perfectly adapted to their development. The unique combination gives firms the benefit of specialized resources that cost less because they are pooled. Biocitech is located close to Raymond Queneau Paris subway station, and is only 20 minutes from Charles de Gaulle airport.

The park is market-oriented and the great majority of its residents generate revenues from the sale of products or services. Furthermore, the firms installed at Biocitech complement one another, thus generating strong synergies and numerous collaborations.

Along with other organizations in the Paris area, Biocitech is a key element in the Medicen Paris Region network, the greater Paris region’s world-class competitiveness hub for health and new therapies.

For further information, go to: http://www.biocitech.com

Mark Tidmarsh

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

mark@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100

Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00

Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->